Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay.

Cardiac biomarkers provide prognostic information in light-chain amyloidosis (AL). Thus, a novel high-sensitivity cardiac troponin T (hs-TnT) assay may improve risk stratification. hs-TnT was assessed in 163 patients. Blood levels were higher with cardiac than renal or other organ involvement and were related to the severity of cardiac involvement. Increased sensitivity was not associated with survival benefit. Forty-seven patients died during follow-up (22.3 ± 1.0 months). Nonsurvivors had higher hs-TnT than survivors. Outcome was worse if hs-TnT more than or equal to 50 ng/L and best less than 3 ng/L. Survival of patients with hs-TnT 3 to 14 ng/L did not differ from patients with moderately increased hs-TnT (14-50 ng/L), but was worse if interventricular septum was more than or equal to 15 mm. Discrimination according to the Mayo staging system was only achieved by the use of the hs-TnT assay, but not by the fourth-generation troponin T assay. Multivariate analysis revealed hs-TnT, NT-proBNP, and left ventricular impairment as independent risk factors for survival. hs-TnT and NT-proBNP predicted survival, even after exclusion of patients with impaired renal function. Plasma levels of the hs-TnT assay are associated with the clinical, morphologic, and functional severity of cardiac AL amyloidosis and could provide useful information for clinicians on cardiac involvement and outcome.

[1]  A. Jaffe,et al.  Analytical validation of a high-sensitivity cardiac troponin T assay. , 2010, Clinical chemistry.

[2]  M. Pfeffer,et al.  A sensitive cardiac troponin T assay in stable coronary artery disease. , 2009, The New England journal of medicine.

[3]  Tobias Reichlin,et al.  Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. , 2009, The New England journal of medicine.

[4]  Stefan Blankenberg,et al.  Sensitive troponin I assay in early diagnosis of acute myocardial infarction. , 2009, The New England journal of medicine.

[5]  H. Goldschmidt,et al.  Staged heart transplantation and chemotherapy as a treatment option in patients with severe cardiac light‐chain amyloidosis , 2009, European journal of heart failure.

[6]  Jennifer E Liu,et al.  Frequencies and types of arrhythmias in patients with systemic light-chain amyloidosis with cardiac involvement undergoing stem cell transplantation on telemetry monitoring. , 2009, The American journal of cardiology.

[7]  H. Katus,et al.  Highly sensitive cardiac troponin T values remain constant after brief exercise- or pharmacologic-induced reversible myocardial ischemia. , 2008, Clinical chemistry.

[8]  H. Goldschmidt,et al.  Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis , 2008, Haematologica.

[9]  A. Dispenzieri,et al.  Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis , 2008, Leukemia & lymphoma.

[10]  H. Goldschmidt,et al.  Rapid progression of left ventricular wall thickness predicts mortality in cardiac light-chain amyloidosis. , 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[11]  Fred S Apple,et al.  Universal definition of myocardial infarction. , 2007, Journal of the American College of Cardiology.

[12]  J. Cohn,et al.  Prognostic Value of Very Low Plasma Concentrations of Troponin T in Patients With Stable Chronic Heart Failure , 2007, Circulation.

[13]  H. Goldschmidt,et al.  Non‐invasive predictors of survival in cardiac amyloidosis , 2007, European journal of heart failure.

[14]  H. Katus,et al.  Suspected cardiac amyloidosis: Endomyocardial biopsy remains the diagnostic gold‐standard , 2007, American journal of hematology.

[15]  D. Seldin,et al.  An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis , 2007, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[16]  H. Katus,et al.  Cardiac troponin T at 96 hours after acute myocardial infarction correlates with infarct size and cardiac function. , 2006, Journal of the American College of Cardiology.

[17]  R. Falk,et al.  Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis , 2005, American journal of hematology.

[18]  H. Goldschmidt,et al.  High‐dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study , 2004, British journal of haematology.

[19]  T. Therneau,et al.  Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  T. Therneau,et al.  Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. , 2004, Blood.

[21]  Richard E Thompson,et al.  Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. , 2004, Journal of the American College of Cardiology.

[22]  R. Califf,et al.  Troponin T levels and risk of 30-day outcomes in patients with the acute coronary syndrome: prospective verification in the GUSTO-IV trial. , 2003, The American journal of medicine.

[23]  T. Therneau,et al.  Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins , 2003, The Lancet.

[24]  A. Balduini,et al.  Serum N-Terminal Pro–Brain Natriuretic Peptide Is a Sensitive Marker of Myocardial Dysfunction in AL Amyloidosis , 2003, Circulation.

[25]  R. Falk,et al.  Prognostic Significance of Ultrasound Myocardial Tissue Characterization in Patients With Cardiac Amyloidosis , 2002, Circulation.

[26]  D. Brutsaert,et al.  New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. , 2002, Circulation.

[27]  E. Braunwald,et al.  Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. , 2001, JAMA.

[28]  G. Palladini,et al.  Holter Monitoring in AL Amyloidosis: Prognostic Implications , 2001, Pacing and clinical electrophysiology : PACE.

[29]  A. Jaffe,et al.  It's time for a change to a troponin standard. , 2000, Circulation.

[30]  A. Keating,et al.  High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant , 1999, Bone Marrow Transplantation.

[31]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[32]  R. Falk,et al.  Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. , 1997, Heart.

[33]  A. Remppis,et al.  Diagnostic Efficiency of Troponin T Measurements in Acute Myocardial Infarction , 1991, Circulation.

[34]  W. O'Fallon,et al.  Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases. , 1986, Blood.

[35]  N. Reichek,et al.  Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. , 1986, The American journal of cardiology.

[36]  J. Seward,et al.  Echocardiographic findings in systemic amyloidosis: spectrum of cardiac involvement and relation to survival. , 1985, Journal of the American College of Cardiology.

[37]  Kyle Ra,et al.  Amyloidosis (AL). Clinical and laboratory features in 229 cases. , 1983 .

[38]  W. Wodzig,et al.  Reference population and marathon runner sera assessed by highly sensitive cardiac troponin T and commercial cardiac troponin T and I assays. , 2009, Clinical chemistry.